Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase

Felicia Stefania Falvella, Marta Caporale, Stefania Cheli, Antonia Martinetti, Rosa Berenato, Claudia Maggi, Monica Niger, Francesca Ricchini, Ilaria Bossi, Maria Di Bartolomeo, Elisa Sottotetti, Francesca Futura Bernardi, Filippo de Braud, Emilio Clementi, Filippo Pietrantonio

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part of combination therapies, cause severe adverse reactions in about 10%–30% of patients. Dihydropyrimidine dehydrogenase (DPD), a key enzyme in the catabolism of 5-fluorouracil, has been intensively investigated in relation to fluoropyrimidine toxicity, and several DPD gene (DPYD) polymorphisms are associated with decreased enzyme activity and increased risk of fluoropyrimidine-related toxicity. In patients carrying non-functional DPYD variants (c.1905+1G>A, c.1679T>G, c.2846A>T), fluoropyrimidines should be avoided or reduced according to the patients’ homozygous or heterozygous status, respectively. For other common DPYD variants (c.496A>G, c.1129-5923C>G, c.1896T>C), conflicting data are reported and their use in clinical practice still needs to be validated. The high frequency of DPYD polymorphism and the lack of large prospective trials may explain differences in studies’ results. The epigenetic regulation of DPD expression has been recently investigated to explain the variable activity of the enzyme. DPYD promoter methylation and its regulation by microRNAs may affect the toxicity risk of fluoropyrimidines. The studies we reviewed indicate that pharmacogenetic testing is promising to direct personalised dosing of fluoropyrimidines, although further investigations are needed to establish the role of DPD in severe toxicity in patients treated for colorectal cancer.

Original languageEnglish
Pages (from-to)8884-8895
Number of pages12
JournalInternational Journal of Molecular Sciences
Volume16
Issue number4
DOIs
Publication statusPublished - Apr 21 2015

Fingerprint

Dihydrouracil Dehydrogenase (NADP)
dehydrogenases
toxicity
Toxicity
polymorphism
Testing
Polymorphism
enzymes
Colorectal Neoplasms
Enzymes
catabolism
cancer
enzyme activity
methylation
Methylation
Enzyme activity
MicroRNAs
Epigenomics
Fluorouracil
genes

Keywords

  • Dihydropyrimidine dehydrogenase
  • Fluoropyrimidines
  • Pharmacogenetics
  • Single nucleotide polymorphisms
  • Toxicity

ASJC Scopus subject areas

  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Spectroscopy
  • Inorganic Chemistry
  • Catalysis
  • Molecular Biology
  • Computer Science Applications

Cite this

Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. / Falvella, Felicia Stefania; Caporale, Marta; Cheli, Stefania; Martinetti, Antonia; Berenato, Rosa; Maggi, Claudia; Niger, Monica; Ricchini, Francesca; Bossi, Ilaria; Di Bartolomeo, Maria; Sottotetti, Elisa; Bernardi, Francesca Futura; de Braud, Filippo; Clementi, Emilio; Pietrantonio, Filippo.

In: International Journal of Molecular Sciences, Vol. 16, No. 4, 21.04.2015, p. 8884-8895.

Research output: Contribution to journalArticle

Falvella, FS, Caporale, M, Cheli, S, Martinetti, A, Berenato, R, Maggi, C, Niger, M, Ricchini, F, Bossi, I, Di Bartolomeo, M, Sottotetti, E, Bernardi, FF, de Braud, F, Clementi, E & Pietrantonio, F 2015, 'Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase', International Journal of Molecular Sciences, vol. 16, no. 4, pp. 8884-8895. https://doi.org/10.3390/ijms16048884
Falvella, Felicia Stefania ; Caporale, Marta ; Cheli, Stefania ; Martinetti, Antonia ; Berenato, Rosa ; Maggi, Claudia ; Niger, Monica ; Ricchini, Francesca ; Bossi, Ilaria ; Di Bartolomeo, Maria ; Sottotetti, Elisa ; Bernardi, Francesca Futura ; de Braud, Filippo ; Clementi, Emilio ; Pietrantonio, Filippo. / Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. In: International Journal of Molecular Sciences. 2015 ; Vol. 16, No. 4. pp. 8884-8895.
@article{67cc5e7ce301437a801928cf08dd214f,
title = "Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase",
abstract = "Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part of combination therapies, cause severe adverse reactions in about 10{\%}–30{\%} of patients. Dihydropyrimidine dehydrogenase (DPD), a key enzyme in the catabolism of 5-fluorouracil, has been intensively investigated in relation to fluoropyrimidine toxicity, and several DPD gene (DPYD) polymorphisms are associated with decreased enzyme activity and increased risk of fluoropyrimidine-related toxicity. In patients carrying non-functional DPYD variants (c.1905+1G>A, c.1679T>G, c.2846A>T), fluoropyrimidines should be avoided or reduced according to the patients’ homozygous or heterozygous status, respectively. For other common DPYD variants (c.496A>G, c.1129-5923C>G, c.1896T>C), conflicting data are reported and their use in clinical practice still needs to be validated. The high frequency of DPYD polymorphism and the lack of large prospective trials may explain differences in studies’ results. The epigenetic regulation of DPD expression has been recently investigated to explain the variable activity of the enzyme. DPYD promoter methylation and its regulation by microRNAs may affect the toxicity risk of fluoropyrimidines. The studies we reviewed indicate that pharmacogenetic testing is promising to direct personalised dosing of fluoropyrimidines, although further investigations are needed to establish the role of DPD in severe toxicity in patients treated for colorectal cancer.",
keywords = "Dihydropyrimidine dehydrogenase, Fluoropyrimidines, Pharmacogenetics, Single nucleotide polymorphisms, Toxicity",
author = "Falvella, {Felicia Stefania} and Marta Caporale and Stefania Cheli and Antonia Martinetti and Rosa Berenato and Claudia Maggi and Monica Niger and Francesca Ricchini and Ilaria Bossi and {Di Bartolomeo}, Maria and Elisa Sottotetti and Bernardi, {Francesca Futura} and {de Braud}, Filippo and Emilio Clementi and Filippo Pietrantonio",
year = "2015",
month = "4",
day = "21",
doi = "10.3390/ijms16048884",
language = "English",
volume = "16",
pages = "8884--8895",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "4",

}

TY - JOUR

T1 - Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase

AU - Falvella, Felicia Stefania

AU - Caporale, Marta

AU - Cheli, Stefania

AU - Martinetti, Antonia

AU - Berenato, Rosa

AU - Maggi, Claudia

AU - Niger, Monica

AU - Ricchini, Francesca

AU - Bossi, Ilaria

AU - Di Bartolomeo, Maria

AU - Sottotetti, Elisa

AU - Bernardi, Francesca Futura

AU - de Braud, Filippo

AU - Clementi, Emilio

AU - Pietrantonio, Filippo

PY - 2015/4/21

Y1 - 2015/4/21

N2 - Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part of combination therapies, cause severe adverse reactions in about 10%–30% of patients. Dihydropyrimidine dehydrogenase (DPD), a key enzyme in the catabolism of 5-fluorouracil, has been intensively investigated in relation to fluoropyrimidine toxicity, and several DPD gene (DPYD) polymorphisms are associated with decreased enzyme activity and increased risk of fluoropyrimidine-related toxicity. In patients carrying non-functional DPYD variants (c.1905+1G>A, c.1679T>G, c.2846A>T), fluoropyrimidines should be avoided or reduced according to the patients’ homozygous or heterozygous status, respectively. For other common DPYD variants (c.496A>G, c.1129-5923C>G, c.1896T>C), conflicting data are reported and their use in clinical practice still needs to be validated. The high frequency of DPYD polymorphism and the lack of large prospective trials may explain differences in studies’ results. The epigenetic regulation of DPD expression has been recently investigated to explain the variable activity of the enzyme. DPYD promoter methylation and its regulation by microRNAs may affect the toxicity risk of fluoropyrimidines. The studies we reviewed indicate that pharmacogenetic testing is promising to direct personalised dosing of fluoropyrimidines, although further investigations are needed to establish the role of DPD in severe toxicity in patients treated for colorectal cancer.

AB - Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part of combination therapies, cause severe adverse reactions in about 10%–30% of patients. Dihydropyrimidine dehydrogenase (DPD), a key enzyme in the catabolism of 5-fluorouracil, has been intensively investigated in relation to fluoropyrimidine toxicity, and several DPD gene (DPYD) polymorphisms are associated with decreased enzyme activity and increased risk of fluoropyrimidine-related toxicity. In patients carrying non-functional DPYD variants (c.1905+1G>A, c.1679T>G, c.2846A>T), fluoropyrimidines should be avoided or reduced according to the patients’ homozygous or heterozygous status, respectively. For other common DPYD variants (c.496A>G, c.1129-5923C>G, c.1896T>C), conflicting data are reported and their use in clinical practice still needs to be validated. The high frequency of DPYD polymorphism and the lack of large prospective trials may explain differences in studies’ results. The epigenetic regulation of DPD expression has been recently investigated to explain the variable activity of the enzyme. DPYD promoter methylation and its regulation by microRNAs may affect the toxicity risk of fluoropyrimidines. The studies we reviewed indicate that pharmacogenetic testing is promising to direct personalised dosing of fluoropyrimidines, although further investigations are needed to establish the role of DPD in severe toxicity in patients treated for colorectal cancer.

KW - Dihydropyrimidine dehydrogenase

KW - Fluoropyrimidines

KW - Pharmacogenetics

KW - Single nucleotide polymorphisms

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84928139184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928139184&partnerID=8YFLogxK

U2 - 10.3390/ijms16048884

DO - 10.3390/ijms16048884

M3 - Article

VL - 16

SP - 8884

EP - 8895

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 4

ER -